M
Morie A. Gertz
Researcher at Mayo Clinic
Publications - 49
Citations - 7022
Morie A. Gertz is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Amyloidosis & Immunoglobulin Light-chain Amyloidosis. The author has an hindex of 28, co-authored 49 publications receiving 6018 citations.
Papers
More filters
Journal ArticleDOI
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
Morie A. Gertz,Raymond L. Comenzo,Rodney H. Falk,Jean Paul Fermand,Bouke P. C. Hazenberg,Philip N. Hawkins,Giampaolo Merlini,Philippe Moreau,Pierre Ronco,Vaishali Sanchorawala,Orhan Sezer,Alan Solomon,Giles Grateau +12 more
TL;DR: A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis, and a consensus was developed defining each organ involved and the criteria for response.
Journal Article
Primary systemic amyloidosis : clinical and laboratory features in 474 cases
Robert A. Kyle,Morie A. Gertz +1 more
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.
TL;DR: Records of all residents of Olmstead County, Minnesota, with a diagnosis of amyloidosis were obtained from the Mayo Clinic and its affiliated hospitals, as well as other medical groups that might have seen local patients for the period January 1, 1950 to December 31, 1989.
Journal ArticleDOI
Amyloidosis: Pathogenesis and New Therapeutic Options
TL;DR: Treatment for AL amyloidosis is highly individualized, determined on the basis of age, organ dysfunction, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response.